Hostname: page-component-6766d58669-bp2c4 Total loading time: 0 Render date: 2026-05-15T03:32:38.376Z Has data issue: false hasContentIssue false
  • English
  • Français

Over-expression of cyclo-oxygenase-2 predicts poor survival of patients with nasopharyngeal carcinoma: a meta-analysis

Published online by Cambridge University Press:  16 March 2020

C-C Sim  and
E U-H Sim
C-C Sim
Affiliation:
Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Kota Samarahan, Malaysia
E U-H Sim*
Affiliation:
Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Kota Samarahan, Malaysia
*
Author for correspondence: Prof Edmund Ui-Hang Sim, Faculty of Resource Science and Technology, Universiti Malaysia Sarawak, Kota Samarahan 94300, Malaysia E-mail: uhsim@unimas.my Fax: +60 825 831 60
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives

The conclusive prognostic significance of cyclo-oxygenase-2 has been determined in various cancers but not in nasopharyngeal carcinoma. Therefore, this study aimed to evaluate the relationship of cyclo-oxygenase-2 expression with the survival outcome and treatment response of nasopharyngeal carcinoma patients via a systematic meta-analysis approach.

Methods

A meta-analysis was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (‘PRISMA’) checklist. The primary clinical characteristics of patients, and hazard ratios with 95 per cent confidence intervals of overall survival data, were tabulated from eligible studies. The relationship of cyclo-oxygenase-2 expression with survival outcome (expressed as hazard ratio) and treatment response (expressed as odds ratio) in nasopharyngeal carcinoma patients was analysed, and explained with the aid of forest plot charts.

Results and conclusion

The pooled hazard ratio for overall survival was 2.02 (95 per cent confidence interval = 1.65–2.47). This indicates that the over-expression of cyclo-oxygenase-2 is significantly associated with the poor survival of nasopharyngeal carcinoma patients. The pooled odds ratio of 0.98 (95 per cent confidence interval = 0.27–3.49) reveals that over-expression of cyclo-oxygenase-2 was not significantly related to the treatment outcome.

Keywords

Cyclooxygenase-2Nasopharyngeal CarcinomaNasopharyngeal NeoplasmsPrognosisMeta-Analysis

Information

Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 134 , Issue 4 , April 2020 , pp. 338 - 343
Copyright
Copyright © JLO (1984) Limited, 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

Footnotes

Prof E U-H Sim takes responsibility for the integrity of the content of the paper

References

He, HL, Lee, YE, Liang, PI, Lee, SW, Chen, TJ, Chan, TC et al. Overexpression of JAK2: a predictor of unfavorable prognosis for nasopharyngeal carcinoma. Future Oncol 2016;12:1887–96CrossRefGoogle ScholarPubMed
Ferlay, J, Shin, HR, Bray, F, Forman, D, Mathers, C, Parkin, DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917CrossRefGoogle ScholarPubMed
Chang, ET, Adami, HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:1765–77CrossRefGoogle ScholarPubMed
Barnes, L, Eveson, JW, Reichart, P, Sidransky, D. World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours, 3rd edn. Lyon: IARC Press, 2005Google Scholar
Fandi, A, Altun, M, Azli, N, Armad, JP, Cvitkovic, E. Nasopharyngeal cancer: epidemiology, staging, and treatment. Semin Oncol 1994;21:382–97Google Scholar
Chan, ATC. Nasopharyngeal carcinoma. Ann Oncol 2010;21:vii308–12CrossRefGoogle ScholarPubMed
Cho, WC. Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 2007;6:1CrossRefGoogle ScholarPubMed
Chou, J, Lin, YC, Kim, J, You, L, Xu, ZD, He, B et al. Nasopharyngeal carcinoma - review of the molecular mechanism of tumorigenesis. Head Neck 2008;30:946–63CrossRefGoogle Scholar
Rusthoven, CG, Lanning, RM, Jones, BL, Amini, A, Koshy, M, Sher, DJ et al. Metastatic nasopharyngeal carcinoma: patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol 2017;124:139–46CrossRefGoogle ScholarPubMed
Yeh, SA, Tang, Y, Lui, CC, Huang, YJ, Huang, EY. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 2005;62:672–9CrossRefGoogle ScholarPubMed
Geara, FB, Sanguineti, G, Tucker, SL, Garden, AS, Ang, KK, Morrison, WH et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of distant metastasis and survival. Radiother Oncol 1997;43:53–61CrossRefGoogle ScholarPubMed
Teo, P, Yu, P, Lee, WY, Leung, SF, Kwan, WH, Yu, KH et al. Significant prognosticators after primary radiotherapy in 903 nondisseminated nasopharyngeal carcinoma evaluated by computer tomography. Int J Radiat Oncol Biol Phys 1996;36:291–304CrossRefGoogle ScholarPubMed
Prawira, A, Oosting, SF, Chen, TW, Delos Santos, KA, Saluja, R, Wang, L et al. Systemic therapies for recurrent or metastatic nasopharyngeal carcinoma: a systematic review. Br J Cancer 2017;117:1743–52CrossRefGoogle ScholarPubMed
Wu, F, Wang, RS, Lu, HM, Wei, B, Feng, GS, Li, GS et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective multicentric clinical study. Radiother Oncol 2014;112:106–11CrossRefGoogle ScholarPubMed
Fendri, A, Khabir, A, Mnejja, W, Sellami-Boudawara, T, Daoud, J, Frikha, M et al. PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma. Cancer Sci 2009;100:2034–9CrossRefGoogle ScholarPubMed
Hughes, PJ, Scott, PMJ, Kew, J, Cheung, DMC, Leung, SF, Ahuja, AT et al. Dysphagia in treated nasopharyngeal cancer. Head Neck 2000;22:393–73.0.CO;2-2>CrossRefGoogle ScholarPubMed
Han, L, Lin, SJ, Pan, JJ, Chen, CB, Zhang, Y, Zhang, XC et al. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer 2010;29:145–50CrossRefGoogle ScholarPubMed
Chua, DT, Nicholls, JM, Sham, JS, Au, GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:11–20Google ScholarPubMed
Su, CK, Wang, CC. Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 2002;54:752–8CrossRefGoogle ScholarPubMed
Shi, W, Pataki, I, Macmillan, C, Pintilie, M, Payne, D, O'Sullivan, B et al. Molecular pathology parameters in human nasopharyngeal carcinoma. Cancer 2002;94:1997–2006CrossRefGoogle ScholarPubMed
Yang, B, Jia, L, Guo, QJ, Ren, H, Hu, YP, Xie, T. Clinicopathological and prognostic significance of cyclooxygenase-2 expression in head and neck cancer: a meta-analysis. Oncotarget 2016;7:47265–77CrossRefGoogle ScholarPubMed
Grivennikov, SI, Greten, FR, Karin, M. Immunity, inflammation, and cancer. Cell 2010;140:883–99CrossRefGoogle Scholar
Li, ZL, Ye, SB, OuYang, LY, Zhang, H, Zhang, XS, Li, J et al. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology 2015;4:e1044712CrossRefGoogle ScholarPubMed
Dannenberg, AJ, Altorki, NK, Boyle, JO, Dang, C, Howe, LR, Weksler, BB et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2001;2:544–51CrossRefGoogle ScholarPubMed
Greenhough, A, Smartt, HJ, Moore, AE, Roberts, HR, Williams, AC, Paraskeva, C et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009;30:377–86CrossRefGoogle ScholarPubMed
Brown, JR, DuBois, RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005;23:2840–55CrossRefGoogle ScholarPubMed
Simonsson, M, Björner, S, Markkula, A, Nodin, B, Jirström, K, Rose, C et al. The prognostic impact of COX-2 expression in breast cancer depends on oral contraceptive history, preoperative NSAID use, and tumor size. Int J Cancer 2017;140:163–75CrossRefGoogle ScholarPubMed
Gupta, GP, Nguyen, DX, Chiang, AC, Bos, PD, Kim, JY, Nadal, C et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007;446:765–70CrossRefGoogle ScholarPubMed
Bakhle, YS. COX-2 and cancer: a new approach to an old problem. Br J Pharmacol 2001;134:1137–50CrossRefGoogle Scholar
Xu, KM, Wang, LF, Shu, HG. COX-2 overexpression increases malignant potential of human glioma cells through Id1. Oncotarget 2014;5:1241–52CrossRefGoogle ScholarPubMed
Huang, ML, Chen, Q, Xiao, JP, Liu, CH, Zhao, XM. Prognostic significance of cyclooxygenase-2 in cervical cancer: a meta-analysis. Int J Cancer 2013;132:363–73CrossRefGoogle ScholarPubMed
Peng, L, Zhou, Y, Wang, YN, Mou, HB, Zhao, Q. Prognostic significance of COX-2 immunohistochemical expression in colorectal cancer: a meta-analysis of the literature. PLoS One 2013;8:e58891CrossRefGoogle ScholarPubMed
Vosooghi, M, Amini, M. The discovery and development of cyclooxygenase-2 inhibitors as potential anticancer therapies. Expert Opin Drug Discov 2014;9:255–67CrossRefGoogle ScholarPubMed
Schellhorn, M, Haustein, M, Frank, M, Linnebacher, M, Hinz, B. Celecoxib increases lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Oncotarget 2005;6:39342–56CrossRefGoogle Scholar
Ben-Batalla, I, Cubas-Cordova, M, Udonta, F, Wroblewski, M, Waizenegger, JS, Janning, M et al. Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs. Oncotarget 2015;6:6341–58CrossRefGoogle ScholarPubMed
US Department of Health and Human Services Food and Drug Administration. Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics: Guidance for Industry. Silver Spring, MD: US Department of Health and Human Services Food and Drug Administration, 2011Google Scholar
Parmar, MK, Torri, V, Stewart, L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998;17:2815–343.0.CO;2-8>CrossRefGoogle ScholarPubMed
Li, YJ, Luo, Y, Xie, XQ, Li, P, Wang, F. The prognostic value of COX-2 expression on circulating tumor cells in nasopharyngeal carcinoma: a prospective analysis. Radiother Oncol 2018;129:396–402CrossRefGoogle ScholarPubMed
Xu, L, Jiang, Y, Zheng, J, Xie, G, Li, J. Aberrant expression of β-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer. Hum Pathol 2013;44:1357–64CrossRefGoogle ScholarPubMed
Pan, J, Tang, T, Xu, L, Lu, JJ, Lin, S, Qiu, S et al. Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma. Head Neck 2012;35:1238–47CrossRefGoogle ScholarPubMed
Kim, YJ, Go, H, Wu, H, Jeon, YK, Park, SW, Lee, SH. Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy. Head Neck 2011;33:1458–66CrossRefGoogle ScholarPubMed
Huang, TL, Li, C, Huang, H, Fang, F. Correlations between expression of epidermal growth factor receptor (EGFR), phosphorylated EGFR, cyclooxygenase-2 and clinicopathological variables and treatment outcomes in nasopharyngeal carcinomas. Chang Gung Med J 2010;33:619–27Google Scholar
Kim, TJ, Lee, YS, Kang, JH, Kim, YS, Kang, CS. Prognostic significance of expression of VEGF and COX-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR. J Surg Oncol 2010;103:46–52CrossRefGoogle Scholar
Loong, SLE, Hwang, JSG, Li, HH, Wee, JTS, Yap, SP, Chua, MLK et al. Weak expression of cyclooxygenase-2 is associated with poorer outcome in endemic nasopharyngeal carcinoma: analysis of data from randomized trial between radiation alone versus concurrent chemo-radiation (SQNP-01). Radiat Oncol 2009;4:23CrossRefGoogle Scholar
Costa, C, Soares, R, Reis-Filho, JS, Leitao, D, Amendoeira, I, Schmitt, FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002;55:429–34CrossRefGoogle ScholarPubMed
Saba, NF, Choi, M, Muller, S, Shin, HJC, Tighiouart, M, Papadimitrakopoulou, VA et al. Role of cyclooxygenase-2 in tumor progression and survival of head and neck squamous cell carcinoma. Cancer Prev Res (Phila) 2009;2:823–9CrossRefGoogle ScholarPubMed
Pan, J, Kong, L, Lin, S, Chen, G, Chen, Q, Lu, JJ. The clinical significance of coexpression of cyclooxygenases-2, vascular endothelial growth factors, and epidermal growth factor receptor in nasopharyngeal carcinoma. Laryngoscope 2008;118:1970–5CrossRefGoogle ScholarPubMed
Turini, ME, Dubois, RN. Cyclooxygenase-2: a therapeutic target. Annu Rev Med 2002;53:35–57CrossRefGoogle ScholarPubMed
Williams, CS, Tsujii, M, Reese, J, Dey, SK, DuBois, RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589–94CrossRefGoogle ScholarPubMed
Soo, R, Putti, T, Tao, Q, Goh, BC, Lee, KH, Kwok-Seng, L et al. Overexpression of cyclooxygenase-2 in nasopharyngeal carcinoma and association with epidermal growth factor receptor expression. Arch Otolaryngol Head Neck Surg 2005;131:147–52CrossRefGoogle ScholarPubMed
Ristimäki, A, Sivula, A, Lundin, J, Lundin, M, Salminen, T, Haglund, C et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632–5Google ScholarPubMed
Chen, JY, Ran, YG, Hong, CQ, Chen, ZJ, You, YJ. Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein. Cytotechnology 2010;62:431–8CrossRefGoogle ScholarPubMed